New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 5, 2014
07:52 EDTMNOVMedicNova announces positive results of MN-001 in advanced NASH mouse model
MediciNova announced positive results from a second preclinical study that examined the potential clinical efficacy of MN-001 for the treatment of advanced NASH, or nonalcoholic steatohepatitis with fibrosis. This study used mice in more advanced stages of NASH as compared to the first study of MN-001 in a NASH mouse model. MN-001 administered orally once daily for 4 weeks, was evaluated in the STAM mouse model of advanced NASH, as measured by histopathology, NAFLD activity score, or NAS, and percent of fibrosis. MN-001 showed anti-NASH and anti-fibrotic effects in the advanced NASH mouse model. NAFLD activity score was significantly reduced in the MN-001 treated group compared to the non-treated group. The reduction was observed consistently in all NAS components including hepatocyte ballooning score, lobular inflammation score, and steatosis score. Percent fibrosis area was also reduced in the MN-001 treated group. In addition, alpha-SMA-positive staining area was significantly reduced in the MN-001 treated group. Based on these results in addition to the results of the first NASH mouse model study reported on January 14, MediciNova requested a meeting with FDA to finalize the trial design for a clinical study of MN-001 in NASH patients.
News For MNOV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 19, 2015
09:19 EDTMNOVOn The Fly: Pre-market Movers
Subscribe for More Information
August 18, 2015
19:48 EDTMNOVMediciNova 5M share Spot Secondary priced at $3.50
Subscribe for More Information
18:32 EDTMNOVOn The Fly: After Hours Movers
Subscribe for More Information
16:01 EDTMNOVMediciNova files to sell common stock, no amount given
MediciNova intends to use the net proceeds received from this offering to fund continued research and development efforts, including with respect to its MN-166 and MN-001 product candidates, and for general corporate purposes, including working capital. Ladenburg Thalmann is acting as sole book-running manager of the offering, and Mizuho Securities and SMBC Nikko are acting as co-managers of the offering.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use